Commenced early feasibility study for VitaFlow® in 2009
Commenced the pivotal clinical trial for VitaFlow®
Completed the first implantation of VitaFlow® for pivotal clinical trial in China
Established Shanghai MicroPort CardioFlow Medtech Corporation
Commenced feasibility study for VitaFlow Liberty®
Completed the pivotal clinical trial enrollment for VitaFlow® in China
VitaFlow® was admitted into the “Green Path” for Innovative Medical Device by the NMPA
Commenced the Registration Clinical Trial for VitaFlow Liberty® in China
Achieved primary endpoints of the clinical trial in China for VitaFlow®
Pre-IPO Investment(series B)
Summitted VitaFlow® registration application to the NMPA
Completed the first implantation of VitaFlow Liberty® for registered clinical trial in China
VitaFlow Liberty® was admitted into the “Green Path” for Innovative Medical Device by the NMPA
Obtained NMPA approval for VitaFlow®
Pre-IPO Investment(series C)
Obtained approval for VitaFlow® and Alwide® in Argentina
Obtained approval for VitaFlow®and Alwide® in Thailand
Pre-IPO Investment (series D)
CardioFlow was listed on the Main Board of the Hong Kong Stock Exchange
Obtained NMPA approval for VitaFlow Liberty®, Alwide® Plus and Angelguide®
Completed the first overseas commercial implantation of VitaFlow® in Argentina
Obtained approval for VitaFlow Liberty® in Argentina
Obtained approval for VitaFlow Liberty®, Alwide® Plus and Angelguide® in Argentina
Completed the first implantation of VitaFlow Liberty® in Colombia
Completed the first implantation of self-developed TMVR system in China
Obtained approval for Alwide® Plus and Angelguide® in Brazil
Obtained approval for Alwide® Plus in Argentina
Obtained approval for VitaFlow Liberty® in Thailand, Russia, and Indonesia
Obtained approval for Alwide® Plus in Thailand, Russia, Indonesia, Saudi Arabia, and Hong Kong, China
Completed the first implantation of VitaFlow Liberty® in Thailand
Completed several pre-market human implantations of VitaFlow Liberty® in Europe
Launched the first clinical application of VitaFlow® III in China
Obtained NMPA approval for AccuSniperTM
Address:Shanghai Pudong Zhangjiang Hi-Tech Park Zhangdong Road 1661
Telephone :(86) (21) 38954600
Fax :(86) (21) 50801305
Email:wcxt@microport.com
Postcode:201203
©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号
互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135
“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.